000300706 001__ 300706
000300706 005__ 20250806114413.0
000300706 0247_ $$2doi$$a10.1158/1078-0432.CCR-24-3275
000300706 0247_ $$2pmid$$apmid:40293274
000300706 0247_ $$2ISSN$$a1078-0432
000300706 0247_ $$2ISSN$$a1557-3265
000300706 0247_ $$2altmetric$$aaltmetric:176519441
000300706 037__ $$aDKFZ-2025-00886
000300706 041__ $$aEnglish
000300706 082__ $$a610
000300706 1001_ $$0P:(DE-He78)b1b2f6c878545eac4cbd9729d8c10b7d$$aWankhede, Durgesh$$b0$$eFirst author$$udkfz
000300706 245__ $$aPrognostic Value of CD8+ T Cells at the Invasive Margin Is Comparable to the Immune Score in Nonmetastatic Colorectal Cancer: A Prospective Multicentric Cohort Study.
000300706 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2025
000300706 3367_ $$2DRIVER$$aarticle
000300706 3367_ $$2DataCite$$aOutput Types/Journal article
000300706 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754390789_9254
000300706 3367_ $$2BibTeX$$aARTICLE
000300706 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300706 3367_ $$00$$2EndNote$$aJournal Article
000300706 500__ $$a#EA:C070#LA:C070# / 2025 May 1;31(9):1711-1718 / D196 =Translationale Immuntherapie vormals D240
000300706 520__ $$aThe Immunoscore predicts colorectal cancer prognosis but faces adoption barriers because of complex software and reimbursement issues. This study used open-source methods to explore a simplified prognostic model in nonmetastatic colorectal cancer by focusing on single T-cell markers.A multicentric prospective cohort study in patients with nonmetastatic colorectal cancer assessed CD3+ and CD8+ tumor-infiltrating lymphocytes (TIL) in the invasive margin (IM) and tumor core (TC) using QuPath. An immune cell score (ICS), based on TIL densities (CD3-IM, CD8-IM, CD3-TC, and CD8-TC), was calculated similarly to the Immunoscore. A split sample approach (70:30) estimated adjusted HRs for cancer-specific survival in training and validation sets. Classification and regression tree analysis identified the most prognostic TIL, and its model was compared with an ICS model for performance (Brier score) and discrimination (concordance probability estimate).Over a median follow-up of 9.0 years, 203 colorectal cancer-specific deaths occurred among 1,260 patients. Classification and regression tree-selected CD8-IM was the most prognostic TIL at a cutoff of 231 cells/mm2. Patients with high CD8-IM had better cancer-specific survival than low CD8-IM in both training (HR 0.58, 95% confidence interval, 0.40-0.84) and validation sets (HR 0.35, 95% confidence interval, 0.21-0.60). Brier scores of CD8-IM and ICS survival models were comparable in both training and validation cohorts, whereas the survival discrimination of CD8-IM slightly outperformed the ICS in the validation set (concordance probability estimate: CD8-IM: 0.748; ICS: 0.730).CD8-IM alone provided prognostic information comparable with the ICS. Simplified, cost-effective TIL assessments could improve clinical translation and guide adjuvant therapy in early-stage colorectal cancer.
000300706 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300706 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300706 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b1$$udkfz
000300706 7001_ $$0P:(DE-He78)028ee60cca729028708496826f077b58$$aKloor, Matthias$$b2$$udkfz
000300706 7001_ $$0P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aEdelmann, Dominic$$b3$$udkfz
000300706 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000300706 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b5$$eLast author$$udkfz
000300706 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-24-3275$$gp. OF1 - OF8$$n9$$p1711-1718$$tClinical cancer research$$v31$$x1078-0432$$y2025
000300706 8767_ $$8APC600632627$$92025-02-20$$d2025-05-08$$eAPC$$jZahlung erfolgt
000300706 909CO $$ooai:inrepo02.dkfz.de:300706$$pVDB$$pOpenAPC$$popenCost
000300706 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b1b2f6c878545eac4cbd9729d8c10b7d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300706 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000300706 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)028ee60cca729028708496826f077b58$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000300706 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000300706 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000300706 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000300706 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300706 9141_ $$y2025
000300706 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000300706 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000300706 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2022$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000300706 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2022$$d2024-12-27
000300706 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000300706 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000300706 9201_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x1
000300706 9201_ $$0I:(DE-He78)D470-20160331$$kD470$$lKKE Angewandte Tumorbiologie$$x2
000300706 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x3
000300706 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x4
000300706 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000300706 980__ $$ajournal
000300706 980__ $$aVDB
000300706 980__ $$aI:(DE-He78)C070-20160331
000300706 980__ $$aI:(DE-He78)D196-20160331
000300706 980__ $$aI:(DE-He78)D470-20160331
000300706 980__ $$aI:(DE-He78)C060-20160331
000300706 980__ $$aI:(DE-He78)HD01-20160331
000300706 980__ $$aAPC
000300706 980__ $$aUNRESTRICTED
000300706 9801_ $$aAPC